Cohort study
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer
- Retrospective cohort study
- population-based
- propensity-score weighted (ATT weights)
- administrative data sets
Authors' conclusion
SGLT2is may reduce the rate of HF hospitalization after anthracycline-containing chemotherapy.
Study context
- Population
- People >65 years with treated DM and no prior heart failure (HF) who received anthracyclines, 2016–2019
- Participants
- 933 people
- Exposure
- SGLT2i vs no SGLT2i after anthracycline chemotherapy
- SGLT2in = 99
- Outcome
- Hospitalization for HF, incident HF diagnoses (in- or out-of-hospital) and documented CVD in future hospitalizations
- Follow-up
- Median 1.6 years
Main finding
As reported in the abstract
SGLT2i
0
events
SGLT2i vs ControlsHazard ratio (95% CI)P value
incident HF diagnosis
0.55(0.23–1.31)
P = 0.18CVD diagnosis
0.39(0.12–1.28)
P = 0.12- HF hospitalization
- HR 0; P < 0.001
- Total events: HF hospitalizations
- 31
- Total events: new HF diagnoses
- 93
- Total events: hospitalizations with documented cardiovascular disease (CVD)
- 74
Observational data: associations, not effects.
Further findings
Incident HF diagnosis (in- or out-of-hospital) · median follow-up 1.6 years
- 93 new HF diagnoses overall
CVD diagnosis in future hospitalizations · median follow-up 1.6 years
- 74 hospitalizations with documented CVD overall
Mortality · median follow-up 1.6 years
- No significant difference in mortality (HR: 0.63; 95% CI: 0.36-1.11)
- P = 0.11
Original publication
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer. JACC CardioOncol. Published 2 May 2023. doi:10.1016/j.jaccao.2023.03.011
Summarised from the published abstract; every number is checked against it